NewAmsterdam CEO exercises options, sells 443,707 shares

NewAmsterdam Pharma Co N.V.

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.

Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.

Insider Trade Summary

Exercise and Sale: 443,707 shares ($14.75M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Davidson Michael H.

Role Chief Executive Officer

Sold 443,707 shs ($14.75M)

Approx. gross sale proceeds $14.75M

Approx. exercise cost $0.00

Approx. pre-tax spread $14.75M

Type	Security	Shares	Price	Value
Exercise	Option (right to buy)	443,707	$0.00	$0.00
Exercise	Ordinary Shares	443,707	$0.00	$0.00
Sale	Ordinary Shares	443,707	$33.25	$14.75M

Holdings After Transaction: Option (right to buy) — 239,267 contracts (Direct); Ordinary Shares — 174,144 shares (Direct)

Footnotes (2)

1. F1. The exercise price of the option is EUR 1.16392.
2. F2. The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NewAmsterdam Pharma (NAMS) report for Michael H. Davidson?

CEO Michael H. Davidson exercised stock options for 443,707 ordinary shares and sold the same number of shares at $33.25 per share on March 2, 2026. The options were exercised at EUR 1.16392 per share under a grant originally dated July 6, 2021.

How many NewAmsterdam Pharma (NAMS) shares and options does the CEO hold after these transactions?

After the transactions, Davidson directly holds 174,144 ordinary shares. He retains 239,267 unexercised options from this specific grant, which expires July 6, 2031.

What type of transaction was reported in this NAMS Form 4?

This was an option exercise-and-sell transaction. Davidson exercised vested stock options (transaction code M) to acquire shares and sold them on the same date (transaction code S). The exercise and sale quantities match, indicating the shares sold were the same shares acquired through the option exercise.

How many options does the NAMS CEO have remaining after this exercise?

After exercising 443,707 options, Davidson retains 239,267 options from this specific grant, which expires July 6, 2031. The options were originally granted at EUR 1.16392 per share.

Why is the exercise price in euros while the sale price is in US dollars?

NewAmsterdam Pharma Co N.V. is a Dutch company (Koninklijke N.V.) whose options are denominated in euros per the original grant terms. The shares trade on NASDAQ in US dollars, so the open-market sale price is reported in USD.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 06:08 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davidson Michael H.

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/02/2026		M		443,707	A	(1)	617,851	D
Ordinary Shares	03/02/2026		S		443,707	D	$33.25	174,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	03/02/2026		M			443,707	(2)	07/06/2031	Ordinary Shares	443,707	$0	239,267	D

Explanation of Responses:

1. The exercise price of the option is EUR 1.16392.

2. The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

	/s/ Michael H. Davidson	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.